Oops, here you go: aacrjournals.org/cancerres/ar...

With the brilliant @mlockley.bsky.social we've been exploring chemo resistance evolution in ovarian cancer. We find resistance has a fitness cost which means resistant cells are outcompeted by sensitive cells when treatment is stopped.
aacrjournals.org/cancerres/ar...

@icr.ac.uk @qmbci.bsky.social

This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...

Smarter chemotherapy approach could delay drug resistance in ovarian cancer - Barts Cancer Institute - Queen Mary University of London Adaptive chemotherapy can prolong survival in lab models of ovarian cancer, according to new results. The findings could pave the way for a more effective and gentler approach to treating ovarian canc...

📰 Can we use the power of evolution to improve ovarian cancer survival?

A surprising approach called adaptive therapy holds promise, according to findings by @mlockley.bsky.social & team at @qmul.ac.uk & @icr.ac.uk.

Read more ➡️ www.bci.qmul.ac.uk/general-news...

#AACR25 #medsky #oncosky🧪

Can we use the power of evolution to improve ovarian cancer treatment? Our latest paper says yes! Online now at Cancer Research. Thanks to
@trevorgraham.bsky.social coauthors and @cancerresearchuk.org for funding.

Delighted to speak at Moffitt Cancer centre last week. Great to share our research and really enjoyed the thought provoking discussions. Many thanks to Joel brown for hosting